Phenotypes Associated with This Genotype

Genotype
MGI:3819385

• Allelic Composition: Smarcb1^tm1Sho/Smarcb1^tm3Sho; Tg(Mx1-cre)1Cgn/?
• Genetic Background: involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6 * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased tumor incidence ( J:80224 )

• mice normal for about 4 weeks after polyI/polyC injection

• begin to develop cancers after 4 weeks

• 100% develop tumors with a median onset of 11 weeks after polyI/polyC injection

• sometimes an increase in circulating tumor cells

increased rhabdomyoma incidence ( J:80224 )

• 3 out of 23 mice with rhabdoid tumors

increased lymphoma incidence ( J:80224 )

• periportal lymphoma in the liver

increased T cell derived lymphoma incidence ( J:80224 )

• 20 of 23 mice have CD8+ T cell lymphomas

• tumor cell types suggestive of malignant lymphocytes

immune system

increased T cell derived lymphoma incidence ( J:80224 )

• 20 of 23 mice have CD8+ T cell lymphomas

• tumor cell types suggestive of malignant lymphocytes

increased eosinophil cell number ( J:80224 )

• increase in circulating eosinophiles

abnormal spleen morphology ( J:80224 )

• effacement of normal architecture

enlarged spleen ( J:80224 )

• sometimes dramatically

abnormal lymph node morphology ( J:80224 )

• effacement of the normal architecture of involved lymph nodes

enlarged lymph nodes ( J:80224 )

hematopoietic system

increased T cell derived lymphoma incidence ( J:80224 )

• 20 of 23 mice have CD8+ T cell lymphomas

• tumor cell types suggestive of malignant lymphocytes

abnormal blood cell morphology/development ( J:80224 )

• often a mild and progressive decrease in blood cell counts

increased eosinophil cell number ( J:80224 )

• increase in circulating eosinophiles

abnormal spleen morphology ( J:80224 )

• effacement of normal architecture

enlarged spleen ( J:80224 )

• sometimes dramatically

liver/biliary system

abnormal liver morphology ( J:80224 )

• periportal lymphomas

enlarged liver ( J:80224 )

• sometimes dramatically

cellular

increased apoptosis ( J:80224 )

• in liver and spleen 18-24 hours after polyI/polyC injection

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:80224 )

• 20 of 23 mice have CD8+ T cell lymphomas

• tumor cell types suggestive of malignant lymphocytes

growth/size/body

enlarged liver ( J:80224 )

• sometimes dramatically

enlarged spleen ( J:80224 )

• sometimes dramatically

muscle

increased rhabdomyoma incidence ( J:80224 )

• 3 out of 23 mice with rhabdoid tumors